Intravenous and Inhaled Antimicrobials at Home in Cystic Fibrosis Patients

被引:1
|
作者
Thigpen, Jim [1 ]
Odle, Brian [1 ]
机构
[1] East Tennessee State Univ, Johnson City, TN USA
关键词
cystic fibrosis; antimicrobial therapy; intravenous antibiotics; aerosolized antibiotics; home health; Pseudomonas aeruginosa; Staphylococcus aureus;
D O I
10.1177/1084822313501322
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The primary clinical characteristics of cystic fibrosis (CF) are malnutrition caused by malabsorption secondary to pancreatic insufficiency, chronic pulmonary infections, and male infertility. The major cause of morbidity and mortality are bronchiectasis and obstructive pulmonary disease. Lung disease in CF is manifested by this chronic lung disease progression, with intermittent episodes of acute worsening of symptoms called pulmonary exacerbations. Once the patient has stabilized, and if suitable care can be arranged, these interventions are often transitioned to the home. This review summarizes important points pertinent to the use of intravenous and inhaled antimicrobials that may be encountered by prescribers, nurses, technicians, and case managers in the home health setting. Appropriate dosing, indications, adverse drug reactions, monitoring parameters, and practicality of both intravenous and inhaled antimicrobials are discussed.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 50 条
  • [31] Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis
    Nazer, Dena
    Abdulhamid, Ibrahim
    Thomas, Ronald
    Pendleton, Sara
    PEDIATRIC PULMONOLOGY, 2006, 41 (08) : 744 - 749
  • [32] Pharmacokinetics of inhaled colistin in patients with cystic fibrosis: authors' response
    Ratjen, F.
    Beier, H.
    Grasemann, H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (01) : 223 - 223
  • [33] Inhaled corticosteroids and Aspergillus fumigatus isolation in cystic fibrosis
    Noni, Maria
    Katelari, Anna
    Dimopoulos, George
    Kourlaba, Georgia
    Spoulou, Vana
    Alexandrou-Athanassoulis, Helen
    Doudounakis, Stavros-Eleftherios
    Tzoumaka-Bakoula, Chryssa
    MEDICAL MYCOLOGY, 2014, 52 (07) : 715 - 722
  • [34] Inhaled Interventions in Cystic Fibrosis: Mucoactive and Antibiotic Therapies
    Hurt, Katharine
    Bilton, Diana
    RESPIRATION, 2014, 88 (06) : 441 - 448
  • [35] Shifting patterns of inhaled antibiotic use in cystic fibrosis
    Moskowitz, Samuel M.
    Silva, Stefanie J.
    Mayer-Hamblett, Nicole
    Pasta, David J.
    Mink, David R.
    Mabie, Jenny A.
    Konstan, Michael W.
    Wagener, Jeffrey S.
    PEDIATRIC PULMONOLOGY, 2008, 43 (09) : 874 - 881
  • [36] Nebulizer choice for inhaled colistin treatment in cystic fibrosis
    Katz, SL
    Ho, SL
    Coates, AL
    CHEST, 2001, 119 (01) : 250 - 255
  • [37] Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients
    Schelstraete, P.
    Van daele, S.
    De Boeck, K.
    Proesmans, M.
    Lebecque, P.
    Leclercq-Foucart, J.
    Malfroot, A.
    Vaneechoutte, M.
    De Baets, F.
    EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (04) : 822 - 829
  • [38] Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis
    Greally, Peter
    Whitaker, Paul
    Peckham, Daniel
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (06) : 1059 - 1067
  • [39] Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis
    Florescu, Marius C.
    Lyden, Elizabeth
    Murphy, Peter J.
    Florescu, Diana F.
    Fillaus, Jennifer
    HEMODIALYSIS INTERNATIONAL, 2012, 16 (03) : 414 - 419
  • [40] Use of Inhaled Tobramycin in Cystic Fibrosis
    Michal Shteinberg
    J. Stuart Elborn
    Advances in Therapy, 2015, 32 : 1 - 9